The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Dean Erhardt
Advertisement
Articles by Dean Erhardt
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=350&fit=crop&auto=format)
A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.
Advertisement
Latest Updated Articles
Proposed Rebates Rule Raises Tough QuestionsJuly 16th 2019
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Agentic AI and the Future of Commercial Excellence in Life Sciences
3
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
4
Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles
5